Testing BRCA1 variants reveals differences in breast cancer risk

Researchers at the Francis Crick Institute have utilized saturation genome editing to identify specific BRCA1 gene mutations that increase breast cancer risk. This study helps clarify the clinical significance of previously ambiguous genetic variants.
Why it matters
Improving the interpretation of genetic testing results can lead to more accurate cancer risk assessments and personalized medical care.
edited by Gaby Clark , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources HAP1 SGE reveals LoF variants in BRCA1. Credit: Nature Genetics (2026). DOI: 10.1038/s41588-026-02832-3 Researchers at the Francis Crick Institute have tested thousands of possible BRCA1 mutations in mammary gland cells to shed light on which genetic variants confer a high risk of developing breast cancer. Research like this holds potential to improve how genetic results are interpreted in the future.
Mutations in the BRCA1 gene, which normally helps to repair damaged DNA, can increase the risk of breast and ovarian cancer. Despite it being one of the most well-known and well-tested cancer risk genes, some mutations in BRCA1 lack clear evidence about their significance for cancer risk.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in